Details of the Drug

General Information of Drug (ID: DMD157S)

Drug Name
Montelukast
Synonyms
Brondilat; Montair; Singular; Apxi toxin; MK 0476; Brondilat (TN); MK-0476; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid; (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [1], [2]
Therapeutic Class
Antiasthmatic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 586.2
Topological Polar Surface Area (xlogp) 7.7
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
62% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.68 mL/min/kg [5]
Elimination
0.2% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.28489 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.002% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.15 L/kg [5]
Chemical Identifiers
Formula
C35H36ClNO3S
IUPAC Name
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
Canonical SMILES
CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
InChI
InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
InChIKey
UCHDWCPVSPXUMX-TZIWLTJVSA-N
Cross-matching ID
PubChem CID
5281040
ChEBI ID
CHEBI:50730
CAS Number
158966-92-8
DrugBank ID
DB00471
TTD ID
D00QET
VARIDT ID
DR00382
INTEDE ID
DR1111
ACDINA ID
D00445

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Antagonist [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [9]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [11]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Leukotriene CysLT1 receptor (CYSLTR1) DTT CYSLTR1 1.96E-02 0.24 0.43
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTP OATP2B1 1.75E-01 -5.73E-02 -1.09E-01
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTP OATP1A2 1.86E-01 4.99E-02 2.27E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.93E-03 -2.19E-01 -4.49E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 1.41E-01 3.13E-01 2.71E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.25E-03 -4.98E-01 -6.49E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.90E-01 2.35E-02 7.88E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Montelukast
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Zafirlukast DMHNQOG Moderate Decreased metabolism of Montelukast caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [72]
Coadministration of a Drug Treating the Disease Different from Montelukast (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Nateglinide DMLK2QH Moderate Decreased metabolism of Montelukast caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [72]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Montelukast caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [73]
Mitotane DMU1GX0 Moderate Increased metabolism of Montelukast caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [73]
Metronidazole DMTIVEN Moderate Decreased metabolism of Montelukast caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [72]
Voriconazole DMAOL2S Moderate Decreased metabolism of Montelukast caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [72]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Montelukast caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [73]
Tucatinib DMBESUA Moderate Decreased metabolism of Montelukast caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [74]
Alpelisib DMEXMYK Moderate Increased metabolism of Montelukast caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Montelukast caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Toremifene DMQYUWG Moderate Decreased metabolism of Montelukast caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [72]
Phenylbutazone DMAYL0T Moderate Decreased metabolism of Montelukast caused by Phenylbutazone mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [72]
Mifepristone DMGZQEF Moderate Decreased metabolism of Montelukast caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [76]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Montelukast caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [77]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Montelukast caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [72]
MK-8228 DMOB58Q Moderate Decreased metabolism of Montelukast caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [72]
Primidone DM0WX6I Moderate Increased metabolism of Montelukast caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Felbamate DM1V5ZS Moderate Increased metabolism of Montelukast caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Montelukast caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Cenobamate DMGOVHA Moderate Increased metabolism of Montelukast caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Montelukast caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Phenobarbital DMXZOCG Moderate Increased metabolism of Montelukast caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Carbamazepine DMZOLBI Moderate Increased metabolism of Montelukast caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [73]
Tazemetostat DMWP1BH Moderate Increased metabolism of Montelukast caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [73]
Miconazole DMPMYE8 Moderate Decreased metabolism of Montelukast caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [72]
Ripretinib DM958QB Moderate Decreased metabolism of Montelukast caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [72]
Sulfinpyrazone DMEV954 Moderate Decreased metabolism of Montelukast caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme. Gout [FA25] [72]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Montelukast caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [72]
Rifampin DMA8J1G Moderate Increased metabolism of Montelukast caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [78]
Rifapentine DMCHV4I Moderate Increased metabolism of Montelukast caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [73]
Delavirdine DM3NF5G Moderate Decreased metabolism of Montelukast caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Efavirenz DMC0GSJ Moderate Decreased metabolism of Montelukast caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Etravirine DMGV8QU Moderate Decreased metabolism of Montelukast caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Gemfibrozil DMD8Q3J Moderate Decreased metabolism of Montelukast caused by Gemfibrozil mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [72]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Montelukast caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [72]
Teriflunomide DMQ2FKJ Moderate Decreased metabolism of Montelukast caused by Teriflunomide mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [72]
PF-06463922 DMKM7EW Moderate Increased metabolism of Montelukast caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [73]
Selpercatinib DMZR15V Moderate Decreased metabolism of Montelukast caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [72]
IPI-145 DMWA24P Moderate Decreased metabolism of Montelukast caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [79]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Montelukast caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [72]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Montelukast caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [73]
Exjade DMHPRWG Moderate Decreased metabolism of Montelukast caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [72]
Rifabutin DM1YBHK Moderate Increased metabolism of Montelukast caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [73]
Imatinib DM7RJXL Moderate Decreased metabolism of Montelukast caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [72]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Montelukast caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [72]
Abametapir DM2RX0I Moderate Decreased metabolism of Montelukast caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [80]
Lefamulin DME6G97 Moderate Decreased metabolism of Montelukast caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [81]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Montelukast caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [72]
Enzalutamide DMGL19D Moderate Increased metabolism of Montelukast caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [73]
Bosentan DMIOGBU Moderate Increased metabolism of Montelukast caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [73]
Dexamethasone DMMWZET Moderate Increased metabolism of Montelukast caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [73]
Nafcillin DMN9RPO Moderate Increased metabolism of Montelukast caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [73]
Leflunomide DMR8ONJ Moderate Decreased metabolism of Montelukast caused by Leflunomide mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [72]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Montelukast caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [82]
Sulfamethizole DMGCHDS Moderate Decreased metabolism of Montelukast caused by Sulfamethizole mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [72]
Elagolix DMB2C0E Moderate Increased metabolism of Montelukast caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [73]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Montelukast caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [72]
⏷ Show the Full List of 56 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Aspartame E00402 134601 Flavoring agent
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Lactic acid E00020 612 Acidulant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Montelukast 4 mg tablet 4 mg Chewable Tablet Oral
Montelukast 5 mg tablet 5 mg Chewable Tablet Oral
Montelukast 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3340).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
8 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
9 Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
10 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
11 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
12 In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
13 Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
24 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
25 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
26 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
27 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
28 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
29 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
30 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
31 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
32 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
33 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
34 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
35 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
36 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
37 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
38 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
39 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
40 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
41 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
42 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
43 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
44 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
45 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
46 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
47 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
48 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
49 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
50 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
51 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
52 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
53 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
54 Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
55 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
56 Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
57 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
58 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
59 Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
60 Drug Interactions in Infectious Diseases.
61 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
62 Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
63 Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
64 Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
65 Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48.
66 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
67 The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
68 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
69 Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
70 Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
71 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
72 Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT "Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast." Clin Pharmacol Ther (2010):. [PMID: 20592724]
73 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
74 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
75 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
76 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
77 Cerner Multum, Inc. "Canadian Product Information.".
78 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
79 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
80 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
81 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
82 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.